Os melhores médicos para o tratamento de Sarcoma de Ewing no exterior — Página 2

O Dr. Mahmoud M. El Zembely chefia o departamento de oncologia pediátrica no Shefaa Al Orman Cancer Center. É especialista em oncologia pediátrica e hematologia maligna. O Dr. El Zembely completou uma bolsa clínica em transplante de medula óssea pediátrica na Seattle Cancer Care Alliance. Trata vários tipos de cancro infantil, incluindo leucemia, linfoma e neuroblastoma.

• Trata todos os tipos de leucemia infantil, linfoma de Hodgkin e linfoma não-Hodgkin.
• Trata tumores sólidos como nefroblastoma, rabdomiossarcoma e cancros infantis raros.
• Realiza transplantes de medula óssea alogénicos e autólogos em pacientes pediátricos.
• Trabalha num centro acreditado pela ESMO que trata 6.000 pacientes anualmente.

O Dr. Raanan Berger é o diretor do Centro de Câncer do Sheba Medical Center. Ele foi incluído na lista de "Melhores Médicos" da Forbes Israel em 2025. O Dr. Berger é especializado em oncologia geniturinária e trata tumores complexos de próstata com radioterapia. Ele completou um pós-doutorado no Dana-Farber/Harvard Cancer Institute.

• Chefia a unidade de pesquisa clínica focada em oncologia molecular.
• Coautor de mais de 20 artigos revisados por pares sobre câncer de próstata e mutações BRCA.
• Membro da Sociedade Americana de Oncologia Clínica (ASCO).
• Realiza terapia sistêmica e radioterapia em um hospital classificado entre os 10 melhores do mundo.

A Dra. Iris Kventsel é hemato-oncologista pediátrica e especialista em transplante de medula óssea no Sheba Medical Center. Ela trata sarcomas infantis, como o sarcoma de Ewing e o osteossarcoma, no Hospital Infantil Edmond e Lily Safra. A Dra. Kventsel integra terapias direcionadas com tratamentos celulares para cânceres infantis complexos. Ela faz parte do corpo docente da Faculdade de Medicina da Universidade de Tel Aviv.

• Especializada em transplante de medula óssea e terapia com células CAR-T para pacientes pediátricos.
• Pesquisa a predisposição genética ao câncer, incluindo a síndrome de Li-Fraumeni e genes de suscetibilidade.
• Publica em periódicos importantes sobre biologia de células-tronco e oncologia cirúrgica (HIPEC).
• Trabalha no Sheba Medical Center, classificado entre os 10 melhores hospitais do mundo.

O Dr. Netanel Meushar chefia o departamento de oncologia óssea no Centro Médico Rambam.

• Especializado no tratamento de cancro ósseo
• Experiente na gestão de casos complexos de sarcoma
• Trabalha num centro médico de referência em Israel

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

A Prof. Myriam Ben Arush é uma especialista reconhecida internacionalmente em Oncologia Pediátrica e Transplante de Medula Óssea, dirigindo a Divisão Pediátrica no Hospital Infantil Ruth Rappaport.

• Recebedora do Prêmio do Ministério da Saúde por trabalho notável
• Premiada com a Legião de Honra na França
• Nomeada uma das médicas mais atenciosas do mundo pela Associação Médica Mundial
• Membro do Grupo de Oncologia Pediátrica dos EUA e de sociedades europeias de câncer

O Prof. Onder Ofluoglu possui de experiência médica, com formação especializada em tumores ósseos e de tecidos moles na Universidade da Pensilvânia e na Universidade da Califórnia.

• Especializado exclusivamente em cirurgia oncológica ortopédica
• Formado em cirurgia de Ilizarov no Centro Científico Ilizarov na Rússia
• Autor ou coautor de mais de 50 documentos científicos
• Membro da Sociedade de Oncologia de Tecidos Conjuntivos e de sociedades europeias de ortopedia

Com mais de _doctor_9338_anos_ de experiência em hematologia e oncologia pediátrica, o Prof. Dogru especializa-se em cancros infantis complexos no Hospital Universitário Biruni.

• Formação especializada em oncologia pediátrica na Universidade de Istambul
• Experiência em transplante de medula óssea
• Membro da Organização Europeia de Transplante de Medula Óssea
• Cargos de professor assistente em várias universidades de prestígio

O Dr. Apak é especializado em hematologia e oncologia pediátrica, com vasta experiência em transplante de medula óssea e terapia com células CAR-T no Hospital Universitário Biruni.

• Mais de _doctor_6792_anos_ liderando a Divisão de Hematologia-Oncologia Pediátrica na Universidade de Istambul-Cerrahpaşa
• Publicou 75 artigos internacionais sobre tratamentos de oncologia pediátrica
• Editor assistente da revista Turkish Pediatrics Archives
• Membro do conselho da Sociedade Pediátrica Turca e da Associação Turca de Medicina do Adolescente

Cirurgião ortopédico

A Prof. Dra. Suna Emir formou-se na Faculdade de Medicina da Universidade de Hacettepe em 1989. Concluiu a sua residência em pediatria na Universidade de Hacettepe de 1990 a 1995. Em 2001, terminou a sua subespecialidade em oncologia pediátrica no Instituto de Oncologia da Universidade de Hacettepe. Tornou-se Professora Associada em 2004. De 2004 a 2009, trabalhou no Hospital de Formação e Investigação em Saúde e Doenças Infantis de Ankara Dışkapı e fundou a Clínica de Oncologia Pediátrica no local. Em 2009, serviu como Subchefe de Oncologia Pediátrica. De 2009 a 2016, foi oficial de formação em hematologia e oncologia pediátrica no Hospital de Formação e Investigação em Saúde e Doenças Infantis, Hematologia e Oncologia de Ankara. Desde 2019, é professora e membro fundador da faculdade de Saúde e Doenças Infantis da Universidade de Atilim.

É especialista em pediatria geral e hematologia e oncologia pediátrica. É ativa na formação de residentes e subespecialidades. Os seus interesses clínicos incluem doenças infantis desde o nascimento até aos 18 anos, linfomas, tumores sólidos, transplante autólogo de medula óssea, anemia, distúrbios hemorrágicos, doenças hereditárias do sangue, hemangiomas e outros tumores benignos, e gânglios linfáticos aumentados.

Chefe do Centro de Oncologia Charité – A Dra. Keilholz traz uma experiência de alto nível para casos complexos de câncer.

• Especializada em oncologia com foco no sarcoma de Ewing
• Lidera um dos principais centros de oncologia de Berlim

Mais de _doctor_3339_anos_ de especialização em oncologia pediátrica – A Dra. López-Ibor lidera a Unidade de Hematologia e Oncologia Pediátrica no HM Montepríncipe.

• Especialista no tratamento de tumores ósseos como o sarcoma de Ewing
• Formada na Universidade de Maryland, um centro de referência em oncologia pediátrica nos EUA
• Ex-chefe de oncologia pediátrica no Hospital Universitario Clínica San Rafael
• Autora de numerosas publicações em revistas nacionais e internacionais

Angelika Eggert é chefe do Departamento de Oncologia Pediátrica no Charité – um dos maiores hospitais universitários da Europa.

• Lidera um departamento importante num hospital europeu de topo
• Foca-se exclusivamente no tratamento do cancro pediátrico
• Acesso aos ensaios clínicos mais recentes para jovens pacientes

O Dr. Kharya, hematologista-oncologista pediátrico, é especializado em transplantes de medula óssea para cânceres infantis no Artemis Hospitals.

• Experiência em hematologia e oncologia pediátrica
• Especializado em transplante de medula óssea
• Focado no tratamento de cânceres infantis

O Professor Demirkaya especializa-se em oncologia pediátrica com 27 anos de experiência de foco no sarcoma de Ewing no Hospital Medicana Bursa.

• Formado no programa de residência em oncologia pediátrica da Universidade Bursa Uludag
• Ex-membro do corpo docente da Faculdade de Medicina da Universidade Bursa Uludag
• Trabalhou no Centro de Hematologia, Oncologia e Transplante de Medula Óssea Pediátrica GATA
• Atual professor de oncologia pediátrica no Medicana Bursa

A Dra. Shruti Kate é especializada em sarcoma de Ewing, com experiência em imunoterapia e terapia metronômica para cânceres avançados. Ela foi formada no Tata Memorial Hospital, um centro de oncologia de referência.

• Doutorado em Oncologia Médica pelo Tata Memorial Hospital
• Membro da ASCO, ESMO e outras sociedades oncológicas de prestígio
• Apresentou pesquisas sobre câncer de pulmão no WCLC 2018
• Experiência no tratamento de tumores pediátricos e tumores sólidos

A Dra. Blanca Lopez Ibor lidera a Unidade de Hematologia e Oncologia Pediátrica no HM Hospitales, com mais de 31 anos de experiência de experiência em oncologia pediátrica.

• Especializada em distúrbios hematológicos e oncológicos em crianças e adolescentes
• Consultora da OMS e da UNESCO em oncologia pediátrica
• Presidente da Fundación Jaime Alonso Abruña, que ajuda crianças com problemas de saúde graves
• Membro da Sociedade Internacional de Oncologia Pediátrica (SIOP)
• Professora na Universidad Complutense de Madrid e na Universidad CEU San Pablo